{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:20:14Z","timestamp":1789129214447,"version":"build-2803163510"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH119314"],"award-info":[{"award-number":["MH119314"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH112737"],"award-info":[{"award-number":["MH112737"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-01523-3","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:47:35Z","timestamp":1740746855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prediction of individual treatment allocation between electroconvulsive therapy or ketamine using the Personalized Advantage Index"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2461-6101","authenticated-orcid":false,"given":"Benjamin S. C.","family":"Wade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Pindale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Luccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Meisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Seiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan A.","family":"Camprodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"1523_CR1","unstructured":"NIMH\u00bb Major Depression. https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression."},{"key":"1523_CR2","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1176\/ps.2009.60.11.1439","volume":"60","author":"BN Gaynes","year":"2009","unstructured":"Gaynes, B. N. et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr. Serv. 60, 1439\u20131445 (2009).","journal-title":"Psychiatr. Serv."},{"key":"1523_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/da.22968","volume":"37","author":"BN Gaynes","year":"2020","unstructured":"Gaynes, B. N. et al. Defining treatment-resistant depression. Depress Anxiety 37, 134\u2013145 (2020).","journal-title":"Depress Anxiety"},{"key":"1523_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMp1006304","volume":"363","author":"MA Hamburg","year":"2010","unstructured":"Hamburg, M. A. & Collins, F. S. The path to personalized medicine. N. Engl. J. Med. 363, 301\u2013304 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1523_CR5","doi-asserted-by":"crossref","unstructured":"Leaver, A. M. et al. Fronto-temporal connectivity predicts ECT outcome in major depression. Front. Psychiatry 9, (2018).","DOI":"10.3389\/fpsyt.2018.00092"},{"key":"1523_CR6","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1017\/S0033291722001659","volume":"52","author":"BSC Wade","year":"2022","unstructured":"Wade, B. S. C. et al. Anterior default mode network and posterior insular connectivity is predictive of depressive symptom reduction following serial ketamine infusion\u2014CORRIGENDUM. Psychol. Med. 52, 2399 (2022).","journal-title":"Psychol. Med."},{"key":"1523_CR7","doi-asserted-by":"crossref","unstructured":"Kang, S. G. & Cho, S. E. Neuroimaging biomarkers for predicting treatment response and recurrence of major depressive disorder. Int. J. Mol. Sci. 21, (2020).","DOI":"10.3390\/ijms21062148"},{"key":"1523_CR8","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1002\/hbm.25620","volume":"42","author":"BSC Wade","year":"2021","unstructured":"Wade, B. S. C. et al. Accounting for symptom heterogeneity can improve neuroimaging models of antidepressant response after electroconvulsive therapy. Hum. Brain Mapp. 42, 5322\u20135333 (2021).","journal-title":"Hum. Brain Mapp."},{"key":"1523_CR9","doi-asserted-by":"publisher","unstructured":"Wade, B., Barbour, T., Ellard, K. & Camprodon, J. Predicting dimensional antidepressant response to repetitive transcranial magnetic stimulation using pretreatment resting-state functional connectivity. https:\/\/doi.org\/10.21203\/RS.3.RS-3204245\/V1 (2023).","DOI":"10.21203\/RS.3.RS-3204245\/V1"},{"key":"1523_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1176\/appi.ajp.2010.09111680","volume":"167","author":"GE Simon","year":"2010","unstructured":"Simon, G. E. & Perlis, R. H. Personalized medicine for depression: can we match patients with treatments? Am. J. Psychiatry 167, 1445\u20131455 (2010).","journal-title":"Am. J. Psychiatry"},{"key":"1523_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/mp.2011.146","volume":"17","author":"AK Malhotra","year":"2012","unstructured":"Malhotra, A. K., Zhang, J. P. & Lencz, T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol. Psychiatry 17, 760\u2013769 (2012).","journal-title":"Mol. Psychiatry"},{"key":"1523_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/mp.2009.89","volume":"16","author":"JL McClay","year":"2011","unstructured":"McClay, J. L. et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol. Psychiatry 16, 76\u201385 (2011).","journal-title":"Mol. Psychiatry"},{"key":"1523_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/ijerph15040771","volume":"15","author":"C Rong","year":"2018","unstructured":"Rong, C. et al. Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder. Int J. Environ. Res Public Health 15, 771 (2018).","journal-title":"Int J. Environ. Res Public Health"},{"key":"1523_CR14","doi-asserted-by":"crossref","unstructured":"Niciu, M. J. et al. Clinical predictors of ketamine response in treatment-resistant major depression. J. Clin. Psychiatry 75, (2014).","DOI":"10.4088\/JCP.13m08698"},{"key":"1523_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/acps.13378","volume":"145","author":"J Luccarelli","year":"2022","unstructured":"Luccarelli, J., McCoy, T. H., Seiner, S. J. & Henry, M. E. Real-world evidence of age-independent electroconvulsive therapy efficacy: a retrospective cohort study. Acta Psychiatr. Scand. 145, 100\u2013108 (2022).","journal-title":"Acta Psychiatr. Scand."},{"key":"1523_CR16","doi-asserted-by":"publisher","first-page":"e83875","DOI":"10.1371\/journal.pone.0083875","volume":"9","author":"RJ DeRubeis","year":"2014","unstructured":"DeRubeis, R. J. et al. The personalized advantage index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS One 9, e83875 (2014).","journal-title":"PLoS One"},{"key":"1523_CR17","doi-asserted-by":"publisher","first-page":"e0140771","DOI":"10.1371\/journal.pone.0140771","volume":"10","author":"MJH Huibers","year":"2015","unstructured":"Huibers, M. J. H. et al. Predicting optimal outcomes in cognitive therapy or interpersonal psychotherapy for depressed individuals using the personalized advantage index approach. PLoS One 10, e0140771 (2015).","journal-title":"PLoS One"},{"key":"1523_CR18","first-page":"490","volume":"9","author":"N Friedl","year":"2020","unstructured":"Friedl, N. et al. Using the personalized advantage index for individual treatment allocation to blended treatment or treatment as usual for depression in secondary care. J. Clin. Med. 2020 9, 490 (2020).","journal-title":"J. Clin. Med. 2020"},{"key":"1523_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1192\/bjp.2017.28","volume":"212","author":"L Van Diermen","year":"2018","unstructured":"Van Diermen, L. et al. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. Br. J. Psychiatry 212, 71\u201380 (2018).","journal-title":"Br. J. Psychiatry"},{"key":"1523_CR20","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate, C. A. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856\u2013864 (2006).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1523_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman, R. M. et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351\u2013354 (2000).","journal-title":"Biol. Psychiatry"},{"key":"1523_CR22","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","volume":"388","author":"A Anand","year":"2023","unstructured":"Anand, A. et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N. Engl. J. Med. 388, 2315\u20132325 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1523_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/HRP.0000000000000368","volume":"31","author":"JA Camprodon","year":"2023","unstructured":"Camprodon, J. A. & Barbour, T. Introduction. Harv. Rev. Psychiatry 31, 97\u2013100 (2023).","journal-title":"Harv. Rev. Psychiatry"},{"key":"1523_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush, A. J. et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 54, 573\u2013583 (2003).","journal-title":"Biol. Psychiatry"},{"key":"1523_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/13651500600885531","volume":"11","author":"IM Cameron","year":"2007","unstructured":"Cameron, I. M. et al. Psychometric properties of the BASIS-24\u00a9 (Behaviour and Symptom Identification Scale-Revised) Mental Health Outcome Measure. Int J. Psychiatry Clin. Pract. 11, 36\u201343 (2007).","journal-title":"Int J. Psychiatry Clin. Pract."},{"key":"1523_CR26","unstructured":"Sundararajan, M. & Najmi, A. The many Shapley values for model explanation. In: Proc. 37th International Conference on Machine Learning, ICML 2020 PartF168147-12, 9210\u20139220 (2019)."},{"key":"1523_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jad.2021.07.035","volume":"294","author":"RS McIntyre","year":"2021","unstructured":"McIntyre, R. S. et al. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. J. Affect. Disord. 294, 592\u2013596 (2021).","journal-title":"J. Affect. Disord."},{"key":"1523_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 46, 399 (2011).","journal-title":"Multivar. Behav. Res."},{"key":"1523_CR29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","volume":"163","author":"MA Brookhart","year":"2006","unstructured":"Brookhart, M. A. et al. Variable selection for propensity score models. Am. J. Epidemiol. 163, 1149\u20131156 (2006).","journal-title":"Am. J. Epidemiol."},{"key":"1523_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1192\/bjp.bp.116.189134","volume":"210","author":"G Fernie","year":"2017","unstructured":"Fernie, G. et al. Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial. Br. J. Psychiatry 210, 422\u2013428 (2017).","journal-title":"Br. J. Psychiatry"},{"key":"1523_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/10503307.2020.1823029","volume":"31","author":"SC Van Bronswijk","year":"2021","unstructured":"Van Bronswijk, S. C. et al. Cross-trial prediction in psychotherapy: external validation of the Personalized Advantage Index using machine learning in two Dutch randomized trials comparing CBT versus IPT for depression. Psychother. Res. 31, 78\u201391 (2021).","journal-title":"Psychother. Res."},{"key":"1523_CR32","doi-asserted-by":"crossref","unstructured":"Friedl, N., Berger, T., Krieger, T., Caspar, F. & Grosse Holtforth, M. Using the Personalized Advantage Index for individual treatment allocation to cognitive behavioral therapy (CBT) or a CBT with integrated exposure and emotion-focused elements (CBT-EE). 30, 763\u2013775 (2019).","DOI":"10.1080\/10503307.2019.1664782"},{"key":"1523_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-023-00817-8","volume":"6","author":"YH Sheu","year":"2023","unstructured":"Sheu, Y. H. et al. AI-assisted prediction of differential response to antidepressant classes using electronic health records. npj Digit. Med. 6, 1\u201312 (2023).","journal-title":"npj Digit. Med."},{"key":"1523_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1192\/bjp.181.3.181","volume":"181","author":"TB \u00dcst\u00fcn","year":"2002","unstructured":"\u00dcst\u00fcn, T. B. & Kessler, R. C. Global burden of depressive disorders: the issue of duration. Br. J. Psychiatry 181, 181\u2013183 (2002).","journal-title":"Br. J. Psychiatry"},{"key":"1523_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/NDT.S198774","volume":"16","author":"D Voineskos","year":"2020","unstructured":"Voineskos, D., Daskalakis, Z. J. & Blumberger, D. M. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr. Dis. Treat. 16, 221\u2013234 (2020).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"1523_CR36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/archpsyc.57.6.581","volume":"57","author":"SH Lisanby","year":"2000","unstructured":"Lisanby, S. H., Maddox, J. H., Prudic, J., Devanand, D. P. & Sackeim, H. A. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch. Gen. Psychiatry 57, 581\u2013590 (2000).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1523_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1176\/appi.ajp.2018.18030290","volume":"175","author":"R Freedman","year":"2018","unstructured":"Freedman, R. et al. Can a Framework Be Established for the Safe Use of Ketamine? Am. J. Psychiatry 175, 587\u2013589 (2018).","journal-title":"Am. J. Psychiatry"},{"key":"1523_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00406-019-01033-w","volume":"270","author":"MM Schmitgen","year":"2020","unstructured":"Schmitgen, M. M. et al. Exploring cortical predictors of clinical response to electroconvulsive therapy in major depression. Eur. Arch. Psychiatry Clin. Neurosci. 270, 253\u2013261 (2020).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"1523_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2836","volume":"37","author":"AP Jesus-Nunes","year":"2022","unstructured":"Jesus-Nunes, A. P. et al. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression. Hum. Psychopharmacol. Clin. Exp. 37, e2836 (2022).","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"1523_CR40","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1176\/appi.ajp.162.5.977","volume":"162","author":"CH Kellner","year":"2005","unstructured":"Kellner, C. H. et al. Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am. J. Psychiatry 162, 977\u2013982 (2005).","journal-title":"Am. J. Psychiatry"},{"key":"1523_CR41","doi-asserted-by":"publisher","unstructured":"Luccarelli, J. et al. Changes in self-reported suicidal ideation during treatment with electroconvulsive therapy: A retrospective cohort study. Acta Psychiatr. Scand. https:\/\/doi.org\/10.1111\/ACPS.13603 (2023).","DOI":"10.1111\/ACPS.13603"},{"key":"1523_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/archpsyc.1978.01770300091010","volume":"35","author":"D Avery","year":"1978","unstructured":"Avery, D. & Winokur, G. Suicide, attempted suicide, and relapse rates in depression. Arch. Gen. Psychiatry 35, 749\u2013753 (1978).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1523_CR43","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.4088\/JCP.14r09528","volume":"76","author":"AU Haq","year":"2015","unstructured":"Haq, A. U., Sitzmann, A. F., Goldman, M. L., Maixner, D. F. & Mickey, B. J. Response of depression to electroconvulsive therapy: A meta-analysis of clinical predictors. J. Clin. Psychiatry 76, 1374\u20131384 (2015).","journal-title":"J. Clin. Psychiatry"},{"key":"1523_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neulet.2016.10.047","volume":"669","author":"M Pinna","year":"2018","unstructured":"Pinna, M. et al. Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review. Neurosci. Lett. 669, 32\u201342 (2018).","journal-title":"Neurosci. Lett."},{"key":"1523_CR45","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jad.2022.12.144","volume":"326","author":"MAJT Blanken","year":"2023","unstructured":"Blanken, M. A. J. T. et al. Sex-specifics of ECT outcome. J. Affect. Disord. 326, 243\u2013248 (2023).","journal-title":"J. Affect. Disord."},{"key":"1523_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpsychires.2019.01.010","volume":"110","author":"MP Freeman","year":"2019","unstructured":"Freeman, M. P. et al. Sex differences in response to ketamine as a rapidly acting intervention for treatment-resistant depression. J. Psychiatr. Res. 110, 166\u2013171 (2019).","journal-title":"J. Psychiatr. Res."},{"key":"1523_CR47","doi-asserted-by":"crossref","unstructured":"Rosenblat, J. D. et al. Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. Psychiatry Res. 303 (2021).","DOI":"10.1016\/j.psychres.2021.114086"},{"key":"1523_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","volume":"51","author":"J Dore","year":"2019","unstructured":"Dore, J. et al. Ketamine Assisted Psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J. Psychoact. Drugs 51, 189\u2013198 (2019).","journal-title":"J. Psychoact. Drugs"},{"key":"1523_CR49","doi-asserted-by":"crossref","unstructured":"Mollaahmetoglu, O. M. et al. \u201cThis is something that changed my life\u201d: a qualitative study of patients\u2019 experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front. Psychiatry 12, 695335 (2021).","DOI":"10.3389\/fpsyt.2021.695335"},{"key":"1523_CR50","doi-asserted-by":"crossref","unstructured":"Walsh, Z. et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open 8, e19(2022).","DOI":"10.1192\/bjo.2022.5"},{"key":"1523_CR51","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/ijnp\/pyac049","volume":"25","author":"A Weigand","year":"2022","unstructured":"Weigand, A. et al. Predicting antidepressant effects of ketamine: the role of the pregenual anterior cingulate cortex as a multimodal neuroimaging biomarker. Int. J. Neuropsychopharmacol. 25, 1003\u20131013 (2022).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1523_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/YCT.0000000000000533","volume":"35","author":"JH Lee","year":"2019","unstructured":"Lee, J. H., Kung, S., Rasmussen, K. G. & Palmer, B. A. Effectiveness of electroconvulsive therapy in patients with major depressive disorder and comorbid borderline personality disorder. J. ECT 35, 44 (2019).","journal-title":"J. ECT"},{"key":"1523_CR53","doi-asserted-by":"crossref","unstructured":"Yip, A. G., Ressler, K. J., Rodriguez-Villa, F., Siddiqi, S. H. & Seiner, S. J. Treatment outcomes of electroconvulsive therapy for depressed patients with and without borderline personality disorder: a retrospective cohort study. J. Clin. Psychiatry 82, 19m13202 (2021).","DOI":"10.4088\/JCP.19m13202"},{"key":"1523_CR54","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41386-023-01540-4","volume":"48","author":"SK Fineberg","year":"2023","unstructured":"Fineberg, S. K. et al. A pilot randomized controlled trial of ketamine in borderline personality disorder. Neuropsychopharmacology 48, 991\u2013999 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"1523_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2023.100688","volume":"15","author":"J Geller","year":"2024","unstructured":"Geller, J. et al. Response to ketamine treatment for major depressive disorder not associated with number of psychiatric comorbidities. J. Affect Disord. Rep. 15, 100688 (2024).","journal-title":"J. Affect Disord. Rep."},{"key":"1523_CR56","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/medicina57030274","volume":"57","author":"J Szarmach","year":"2021","unstructured":"Szarmach, J., Cuba\u0142a, W. J., W\u0142odarczyk, A. & Ga\u0142uszko-W\u0119gielnik, M. Somatic comorbidities and cardiovascular safety in ketamine use for treatment-resistant depression. Medicines 57, 274 (2021).","journal-title":"Medicines"},{"key":"1523_CR57","doi-asserted-by":"publisher","first-page":"108431","DOI":"10.1016\/j.pharmthera.2023.108431","volume":"246","author":"JN Johnston","year":"2023","unstructured":"Johnston, J. N., Henter, I. D. & Zarate, C. A. The antidepressant actions of ketamine and its enantiomers. Pharm. Ther. 246, 108431 (2023).","journal-title":"Pharm. Ther."},{"key":"1523_CR58","doi-asserted-by":"publisher","first-page":"22m14548","DOI":"10.4088\/JCP.22m14548","volume":"84","author":"B Singh","year":"2023","unstructured":"Singh, B. et al. Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study. J. Clin. Psychiatry 84, 22m14548 (2023).","journal-title":"J. Clin. Psychiatry"},{"key":"1523_CR59","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamapsychiatry.2019.3671","volume":"77","author":"RA Poldrack","year":"2020","unstructured":"Poldrack, R. A., Huckins, G. & Varoquaux, G. Establishment of best practices for evidence for prediction: a review. JAMA Psychiatry 77, 534\u2013540 (2020).","journal-title":"JAMA Psychiatry"},{"key":"1523_CR60","doi-asserted-by":"publisher","first-page":"927312","DOI":"10.3389\/fbinf.2022.927312","volume":"2","author":"N Pudjihartono","year":"2022","unstructured":"Pudjihartono, N., Fadason, T., Kempa-Liehr, A. W. & O\u2019Sullivan, J. M. A Review of feature selection methods for machine learning-based disease risk prediction. Front. Bioinform. 2, 927312 (2022).","journal-title":"Front. Bioinform."},{"key":"1523_CR61","doi-asserted-by":"crossref","unstructured":"Wade, B. S. C., Joshi, S. H., Gutman, B. A. & Thompson, P. M. Machine learning on high dimensional shape data from subcortical brain surfaces: a comparison of feature selection and classification methods. Pattern Recognit. 63, 731\u2013739 (2017).","DOI":"10.1016\/j.patcog.2016.09.034"},{"key":"1523_CR62","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.pmrj.2012.07.002","volume":"4","author":"KL Sainani","year":"2012","unstructured":"Sainani, K. L. Propensity scores: uses and limitations. PM&R 4, 693\u2013697 (2012).","journal-title":"PM&R"},{"key":"1523_CR63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/bja\/aet290","volume":"112","author":"GN Okoli","year":"2014","unstructured":"Okoli, G. N., Sanders, R. D. & Myles, P. Demystifying propensity scores. Br. J. Anaesth. 112, 13 (2014).","journal-title":"Br. J. Anaesth."},{"key":"1523_CR64","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1097\/00005650-200412000-00010","volume":"42","author":"SV Eisen","year":"2004","unstructured":"Eisen, S. V., Normand, S. L., Belanger, A. J., Spiro, A. & Esch, D. The Revised Behavior and Symptom Identification Scale (BASIS-R): reliability and validity. Med. Care 42, 1230\u20131241 (2004).","journal-title":"Med. Care"},{"key":"1523_CR65","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/NMD.0b013e318261413d","volume":"200","author":"A Yeung","year":"2012","unstructured":"Yeung, A. et al. The quick inventory of depressive symptomatology, clinician-rated and Self-report: a psychometric assessment in Chinese Americans with major depressive disorder. J. Nerv. Ment. Dis. 200, 712 (2012).","journal-title":"J. Nerv. Ment. Dis."},{"key":"1523_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"D Ho","year":"2011","unstructured":"Ho, D., Imai, K., King, G. & Stuart, E. A. MatchIt: nonparametric preprocessing for parametric causal inference. J. Stat. Softw. 42, 1\u201328 (2011).","journal-title":"J. Stat. Softw."},{"key":"1523_CR67","unstructured":"Greifer, N. Cobalt: covariate balance tables and plots. https:\/\/ngreifer.github.io\/cobalt\/ (2024)."},{"key":"1523_CR68","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"key":"1523_CR69","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.brs.2020.08.009","volume":"13","author":"J Luccarelli","year":"2020","unstructured":"Luccarelli, J., McCoy, T. H., Seiner, S. J. & Henry, M. E. Charge required to induce a seizure during initial dose titration using right unilateral brief pulse electroconvulsive therapy. Brain Stimul. 13, 1504\u20131506 (2020).","journal-title":"Brain Stimul."},{"key":"1523_CR70","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/YCT.0000000000000768","volume":"37","author":"J Luccarelli","year":"2021","unstructured":"Luccarelli, J. et al. Duration of treatment in electroconvulsive therapy among patients beginning with acute course right unilateral brief pulse stimuli. J. ECT 37, 238\u2013242 (2021).","journal-title":"J. ECT"},{"key":"1523_CR71","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695\u2013699 (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1523_CR72","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman, L. Random forests. Mach. Learn. 45, 5\u201332 (2001).","journal-title":"Mach. Learn."},{"key":"1523_CR73","doi-asserted-by":"crossref","unstructured":"Wright, M. N. & Ziegler, A. Ranger: a fast implementation of random forests for high dimensional data in C++ and R. J. Stat. Softw .77, 1\u201317 (2015).","DOI":"10.18637\/jss.v077.i01"},{"key":"1523_CR74","doi-asserted-by":"crossref","unstructured":"Lewis, M. J. et al. nestedcv: an R package for fast implementation of nested cross-validation with embedded feature selection designed for transcriptomics and high-dimensional data. Bioinform. Adv. 3, vbad048 (2023).","DOI":"10.1093\/bioadv\/vbad048"},{"key":"1523_CR75","unstructured":"R: The R Project for Statistical Computing. https:\/\/www.r-project.org\/."},{"key":"1523_CR76","unstructured":"Lundberg, S. M., Erion, G. G. & Lee, S.-I. Consistent individualized feature attribution for tree ensembles. (2018)."},{"key":"1523_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-016-0995-8","volume":"17","author":"MN Wright","year":"2016","unstructured":"Wright, M. N., Ziegler, A. & K\u00f6nig, I. R. Do little interactions get lost in dark random forests? BMC Bioinform. 17, 145 (2016).","journal-title":"BMC Bioinform."},{"key":"1523_CR78","doi-asserted-by":"publisher","first-page":"114231","DOI":"10.1016\/j.psychres.2021.114231","volume":"306","author":"TT Le","year":"2021","unstructured":"Le, T. T. et al. Ketamine for psychotic depression: an overview of the glutamatergic system and ketamine\u2019s mechanisms associated with antidepressant and psychotomimetic effects. Psychiatry Res. 306, 114231 (2021).","journal-title":"Psychiatry Res."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01523-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01523-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01523-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:47:51Z","timestamp":1740746871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01523-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-01523-3","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L. has received funding from Harvard Medical School and the National Institute of Mental Health. He has received equity from Revival Therapeutics. J.A.C. is an inventor of patents and patent applications on neuromodulation targeting methods held by Massachusetts General Hospital, is a member of the scientific advisory board of Hyka and Flow Neuroscience, and has been a paid consultant for Mifu Technologies, Neuroelectrics, and LivaNova. The remaining authors report no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}